Key Highlights
- Capricor Therapeutics (NASDAQ:CAPR) traded at USD 8.23 in a published screener snapshot, down 7.71% in the latest session but up 31.93% over one week, ranking among small cap weekly gainers.
- The FDA extended its decision date for the deramiocel Biologics license application to November 22, 2026 from August 22, 2026 after a major amendment with 24 month open label extension data and a narrower upper limb indication.
- HOPE-3, a Phase 3 placebo controlled trial of 106 patients, had 12 month results published in July 2026, and open label extension data on upper limb function followed on October 5, 2026.
- The company reported no revenue, a net loss of USD 129.4 million, or USD 2.23 per share, and a Market Value of USD 384.3 million at USD 5.88 on July 12, 2026.
What Moved Capricor Therapeutics (Up 31.93% in 1W)
Capricor, a clinical stage biotech developing deramiocel for Duchenne muscular dystrophy, traded at USD 8.23 in the published screener snapshot, up 31.93% in one week but down 7.71% in the latest session. From USD 5.88 on July 12, 2026 the price is about 40.0% higher (calculated). The company announced on June 26, 2026 an FDA advisory committee meeting for July 29, 2026, and five year HOPE-2 extension data. The original decision date was August 22, 2026, and the agency moved it to November 22, 2026, a Sunday, after treating the company amendment as major.
Why Re-Rating Happens in a Stock Like This
No new single catalyst for this particular week was identified in the pages reviewed. The general mechanism is a binary regulatory event: when a decision date approaches, traders add exposure on positive trial data and the share price can swing sharply either way. The amendment added 24 month open label extension data, robustness analyses and a narrower indication on upper limb function, and the Lancet publication and October 5, 2026 data at the World Muscle Society congress kept attention high. A shareholder, Kaos Capital, asked on August 21, 2026 for a board meeting within 15 Business days. A published consensus target of USD 27.00 is 228% above USD 8.23 (calculated), and is not a forecast.
Valuation, Liquidity and Risks After a Run
With USD 0 revenue, valuation rests on the regulatory outcome. Market value was USD 384.3 million on July 12, 2026, and about USD 538 million at USD 8.23 (calculated from roughly 65.4 million shares). The 3M, 6M and YTD figures were not visible in the snapshot, though the stock had fallen about 77.5% year to date by late August 2026. After a 31.93% weekly gain, a small number of trades can move the price and spreads can be wide. A rejection or delay could reverse the move, and a new offering to fund the launch could dilute holders. The 7.71% latest session drop shows volatility.
Where Things Stand
Capricor Therapeutics (NASDAQ:CAPR) rose 31.93% in a week as investors positioned ahead of the November 22, 2026 FDA decision date for deramiocel, though no single catalyst for the week was confirmed. It sits among the small cap weekly gainers in a published screener snapshot, behind leaders such as Universal Logistics at 83.75%. At USD 8.23 it has recovered from USD 5.88 in July, yet the outcome is binary and a small cap can reverse quickly.



_11_17_2026_20_37_58_946960.jpg)


Please wait processing your request...